AVI 6003

Drug Profile

AVI 6003

Alternative Names: AVI-6003; AVI-7287/AVI-7288; AVI-7288/AVI-7287

Latest Information Update: 09 Aug 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AVI BioPharma; United States Army Medical Research Institute of Infectious Diseases
  • Developer Sarepta Therapeutics; United States Army Medical Research Institute of Infectious Diseases
  • Class Antisense elements; Antisense oligonucleotides; Antivirals
  • Mechanism of Action RNA interference; Viral RNA inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Marburg virus disease

Most Recent Events

  • 09 Aug 2012 Discontinued - Phase-I for Marburg virus disease in USA (IV)
  • 12 Jul 2012 AVI BioPharma is now called Sarepta Therapeutics
  • 09 Feb 2012 Final adverse events data from a phase I trial in Marburg virus disease (in volunteers, prevention) released by AVI BioPharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top